ASCO-GI data sets up wider use of Ipsen's Onivyde

Ipsen and partner Servier hope to extend the uses of their pancreatic cancer therapy Onivyde into the first-line treatment setting, assisted by new phase 3 data reported at the ASCO-GI 2023

Amgen eyes pancreatic cancer use for its pathfinder KRAS dru...

Armed with new clinical trial results, Amgen is expanding studies of its KRAS inhibitor Lumakras in pancreatic cancer, as it tries to extend the label for the first-in-class drug beyond its

RedX Pharma CEO focuses on pipeline that found Lilly's risin...

Back in 2017, the UK biotech RedX Pharma had to sell its prized asset after administrators stepped in to stave off a debt crisis, with Loxo Oncology snapping up the BTK inhibitor for $40 mi

AI health record scanning could identify pancreatic cancer e...

Artificial intelligence (AI) could hold the key to identifying people at risk of pancreatic cancer early, allowing them to start potentially life-saving treatment more quickly.

‘More people will die from pancreatic cancer’: How COVID-19 ...

More people with pancreatic cancer will die from the disease if the COVID-19 crisis continues to demand the lion’s share of clinical time and resources.

AZ, Merck add pancreatic cancer to Lynparza’s growing use li...